College of Medicine, University of Florida, Gainesville, Florida.
Pediatr Res. 2018 Mar;83(3):559-563. doi: 10.1038/pr.2017.295. Epub 2018 Jan 3.
Diarrheal disease is a worldwide problem that still causes significant morbidity and mortality among children. Currently, oral rehydration solution (ORS) is the standard of care for acute diarrhea in pediatric patients. Although effective in reducing mortality, ORS does not alleviate diarrheal symptoms, thus reducing caregiver compliance and therapeutic efficacy. This article will briefly review the current problem of pediatric diarrhea and the shortcomings of current therapies; however, the focus of this review is to examine the intestinal calcium-sensing receptor (CaSR). The author summarizes the evidence suggesting that targeting the CaSR will enable clinicians to address all four major pathophysiological mechanisms of diarrheal disease, and substantiates the need for future research regarding this therapy.
腹泻病是一个全球性问题,仍然导致儿童发病率和死亡率居高不下。目前,口服补液盐(ORS)是儿科患者急性腹泻的标准治疗方法。尽管 ORS 可有效降低死亡率,但它并不能缓解腹泻症状,从而降低了护理人员的依从性和治疗效果。本文将简要回顾儿科腹泻的现状和当前治疗方法的不足之处;然而,本文的重点是研究肠道钙敏感受体(CaSR)。作者总结了一些证据,表明靶向 CaSR 将使临床医生能够解决腹泻病的所有四个主要病理生理机制,并证实了对此种治疗方法进行未来研究的必要性。